Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
François Girardin, Oriol Manuel, Catia Marzolini, Thierry Buclin
Topics & Concepts
RitonavirCobicistatSaquinavirPharmacologyPharmacokineticsDrugMedicineBioavailabilityAntiretroviral drugProbenecidAtazanavirIndinavirElvitegravirHuman immunodeficiency virus (HIV)VirologyViral loadAntiretroviral therapyHIV/AIDS drug development and treatmentPharmacological Effects and Toxicity StudiesAntibiotics Pharmacokinetics and Efficacy